Becton, Dickinson and Company announced it repurchased $750M in BD stock to date in FY25. In addition, the board has authorized the company to repurchase up to 10M shares of BD common stock in addition to the shares that remain available under the board’s previous authorization in 2021. The authorizations provide the company the ability to repurchase shares of its common stock through open market purchases, privately negotiated transactions or other methods.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $280 from $275 at Piper Sandler
- Becton Dickinson, Biosero announce framework collaboration agreement
- Becton Dickinson price target lowered to $278 from $312 at Barclays
- Becton Dickinson announces additional investments in manufacturing
- Becton Dickinson announces BD Onclarity HPV Assay added to ASCCP guidelines